[ad_1]
The American company “Moderna” announced that the clinical trials of its experimental vaccine against Covid-19, which are among the most advanced, will not show results before November 25, thus excluding any commercial commercialization of this vaccine before the presidential elections. Americans scheduled for November 3.
“We will have enough safety data on November 25 to be able to submit an emergency request to the Food and Drug Administration, as long as the data is,” Moderna CEO Stephane Bansel said during a conference organized by the “Financial Times “. Safety is good, which means the vaccine is considered safe. “
Moderna, in addition to Pfizer and Johnson & Johnson, is conducting the third phase of clinical trials on experimental vaccines for the virus, during which tens of thousands of volunteers are injected with the vaccine and a similar number with a placebo vaccine, with in order to verify the effectiveness and safety of the vaccine.
There is a fourth vaccine in the United States that reached this third stage, but clinical trials on it were temporarily suspended, it is a vaccine developed by the company “AstraZeneca” in cooperation with the University of Oxford.
US President Donald Trump has repeatedly expressed hope that a vaccine will be found before the November 3 election, prompting fears among public health experts of putting political pressure on the regulatory process. for the adoption of vaccines.
Only Pfizer expects to achieve results by the end of October, days before the voting date, which will allow the company to immediately file an application for a license from the Food and Drug Administration. The test protocol provides relatively fast data analysis.
But scientists and statisticians in the field of biology and experts in clinical trials have warned of the risks of granting an accelerated approval and preferred to test the vaccine for a few more months to ensure its effectiveness and possible side effects.
[ad_2]
